Portal de Periódicos da CAPES

Revisão Acesso aberto Produção Nacional

BIBTEX RIS

Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites

2014; Elsevier BV; Volume: 55; Issue: 3 Linguagem: Inglês

10.1016/j.rbr.2014.06.006

1809-4570

Lícia Maria Henrique da Mota, Bóris Afonso Cruz, Claiton Viegas Brenol, Daniel Feldman Pollak, Geraldo da Rocha Castelar Pinheiro, Iêda Maria Magalhães Laurindo, Ivânio Alves Pereira, Jozélio Freire de Carvalho, Manoel Barros Bértolo, Marcelo Antônio Amaro Pinheiro, Max Victor Carioca Freitas, Nílzio Antônio da Silva, Paulo Louzada‐Júnior, Percival D. Sampaio‐Barros, Rina Dalva Neubarth Giorgi, Rodrigo Aires Corrêa Lima, Luís Eduardo Coelho Andrade,

Chronic Lymphocytic Leukemia Research

The treatment of autoimmune rheumatic diseases has gradually improved over the last half century, which has been expanded with the contribution of biological therapies or immunobiopharmaceuticals. However, we must be alert to the possibilities of undesirable effects from the use of this class of medications. The Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia/SBR) produced a document based on a comprehensive literature review on the safety aspects of this class of drugs, specifically with regard to the treatment of rheumatoid arthritis (RA) and spondyloarthritides. The themes selected by the participating experts, on which considerations have been established as the safe use of biological drugs, were: occurrence of infections (bacterial, viral, tuberculosis), infusion reactions, hematological, neurological, gastrointestinal and cardiovascular reactions, neoplastic events (solid tumors and hematologic neoplasms), immunogenicity, other occurrences and vaccine response. For didactic reasons, we opted by elaborating a summary of safety assessment in accordance with the previous themes, by drug class/mechanism of action (tumor necrosis factor antagonists, T-cell co-stimulation blockers, B-cell depletors and interleukin-6 receptor blockers). Separately, general considerations on safety in the use of biologicals in pregnancy and lactation were proposed. This review seeks to provide a broad and balanced update of that clinical and experimental experience pooled over the last two decades of use of immunobiological drugs for RA and spondyloarthritides treatment.